"Are we doing business the wrong way around in the Life Science Sector?"

For the past 50 years we have created solutions for problems that we thought would solve the problems. Pharmaceuticals have created big block buster drugs which were great for that time but now we realise that these drugs were in fact only tested

Storsatsning i Uppsala – life science-område ska växa kraftigt

Uppsalas största life science-kluster ska bli större – mycket större. Området i Fyrislund ska tredubblas till ytan och ge plats för ytterligare 12 000 arbetsplatser, enligt ett förslag till ny detaljplan som nu är ute på samråd.

She is Sweden´s new Minister of Healthcare

Today, Tuesday, Swedish Prime Minister Ulf Kristersson, who leads the Moderate Party and the centre-right coalition in Sweden, presented the government's new ministers. Christian Democrat Jakob Forssmed gets the role of Minister for Social Affairs and Acko Ankarberg Johansson (also of the Christian Democrat Party) becomes Minister for Health Care.

The TFS family is growing

TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the TFS family welcomes new members.

66 barn misstänks ha dött av hostmedicin – WHO utfärdar varning

WHO varnar för fyra sorters hostmedicin från det indiska läkemedelsbolaget Maiden Pharmaceuticals, vars medicin tros ha orsakat 66 barns död i Gambia.

Business Sweden’s new team is rolling out the blue-yellow carpet

According to Business Sweden’s life science team, the combination of substantial medical know-how and an ever-flourishing tech sector is a success factor for Sweden. “It’s a perfect storm, a beneficent, perfect storm,” says Programme Manager Britta Stenson.

FOKUS Patient turns international

FOKUS Patient is arranging conferences over 3 days in October, and this year, the focus will be on international collaborations.

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s

Gel av spindeltrådsprotein utvecklas för biomedicinsk användning

Spindeltrådens märkliga egenskaper kommer till användning när svenska forskare undersöker nya, potentiella metoder för bland annat regenerativ medicin och läkemedelsformulering.

Ny styrelseordförande till Epista Life Science

Per Kogut blir ny styrelseordförande och Ronny Roos lämnar därmed ordförandeposten, men stannar kvar i styrelsen.

Collaboration for a simpler production of gene therapies launched

A collaboration between universities and companies aims at providing better production methods for the development of gene therapies. The initiative is led by Johan Rockberg, Professor at KTH.

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt does not mind his language when describing the shortcomings of today’s healthcare system. “It makes me extremely frustrated,” he says.

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Elekta lanserar ny gamma knife

Elekta firar 50 år i år och lanserar det nya systemet Elekta Esprit, som ska ge snabbare behandlingstid och bli mer patientvänlig.

Elicera develops CAR-T against solid tumours – may become the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.

“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”

“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimension. But what if the leading life science nations, Denmark and Sweden, joined forces, took the lead and pioneered Nordic life science collaboration? Wouldn´t we then be able to "bake a bigger cake?", writes Anette Steenberg and Ulf G. Andersson in a debate article.

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences", writes Giulia Gaudenzi in a column.

Pharma Outsourcing igång på Stockholm Waterfront

Vd-byte på Cross ska stärka marknadssidan

Lundabaserade medicinteknikbolaget Cross Technology Solutions rekryterar Titti Lundgren som ny vd.

Medicheck anställer ny Sverigechef

Emilie Erhardt Winiarski blir Sverigechef för vårdbolaget Medicheck.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Biotechprojekt får miljonstöd

Stamcellsterapi av covid-19-relaterad ARDS och mini-hjärnor för AI-baserad läkemedels-screening. Det är två av projekten som får stöd när Swelife och Medtech4health delar ut 36 miljoner kronor.

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to fundamental changes to the regulatory system? In a column Marie Gårdmark, CEO and Senior Consultant at RegSmart Life Science, develops her views on this subject.